Copyright © 2009-2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. All rights reserved.
New Jersey-based pharmaceutical company Merck has sued generic drug maker Fresenius for infringing patents relating to its anti-fungal injection Cancidas (caspofungin acetate).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Merck, Fresenius, Cancidas, District Court of Delaware, Hatch-Waxman Act